Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

Other Warnings/Precautions

• Insomnia may be a symptom of a primary disorder, rather than a primary disorder itself

• Use only with extreme caution in patients with impaired respiratory function or obstructive sleep apnea

• Ramelteon should only be administered at bedtime

• May decrease testosterone levels or increase prolactin levels, but the clinical significance of this is unknown

• Patients who develop angioedema after treatment with ramelteon should not be rechallenged

Do Not Use

• With fluvoxamine

• In patients with severe hepatic impairment

• If there is a proven allergy to ramelteon

RAMELTEON: SPECIAL POPULATIONS

Renal Impairment

• Dose adjustment not generally necessary

Hepatic Impairment

• Use with caution in patients with moderate hepatic impairment

• Not recommended for use in patients with severe impairment

Cardiac Impairment

• Dosage adjustment may not be necessary

Elderly

• No adjustment necessary

• Greater absorption and higher plasma drug concentrations but no increase in side effects

Children and Adolescents

• Safety and efficacy have not been established

Pregnancy

• Risk Category C [some animal studies show adverse effects; no controlled studies in humans]

Breast Feeding

• Unknown if ramelteon is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk

✽ Recommended either to discontinue drug or bottle feed

RAMELTEON: THE ART OF PSYCHOPHARMACOLOGY

Potential Advantages

• Those who require long-term treatment

• Those who need a hypnotic but have a past history of substance abuse

• Possibly for circadian rhythm disturbances

Potential Disadvantages

• More expensive than some other hypnotics

• For patients who require sedation

Primary Target Symptoms

• Time to sleep onset

Pearls

• First in a new class of agents, chronohypnotics, that act upon circadian rhythms by stimulating melatonin receptors in the brain’s “pacemaker,” namely the suprachiasmatic nucleus

• Theoretically, stimulation of melatonin 1 receptors mediates the suppressive effects of melatonin on the suprachiasmatic nucleus

• Theoretically, stimulation of melatonin 2 receptors mediates the phase shifting effect of melatonin

• Ramelteon may act by promoting the proper maintenance of circadian rhythms underlying a normal sleep-wake cycle

• Thus, ramelteon may also prove effective for treatment of circadian rhythm disturbances such as shift work sleep disorder and jet lag

• Lack of actions on GABA systems, which may be related to lack of apparent abuse liability

• Only approved hypnotic agent that is not scheduled and is considered to have no abuse liability

• No evidence that ramelteon worsens apnea/hypopnea index in chronic obstructive pulmonary disease or in obstructive sleep apnea, but not recommended in severe cases

✽ May be preferred over benzodiazepines because of its rapid onset of action, short duration of effect, and safety profile

• Rebound insomnia does not appear to be common

• May have fewer carryover side effects than some other sedative hypnotics

Suggested Reading

Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7(1):17–24.

Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Okhawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48(2):301–10.

McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19(12):1057–65.

Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp Gerontol 2005;40(12):911–25.

REBOXETINE

REBOXETINE: THERAPEUTICS

Brands

• Norebox

• Edronax

see index for additional brand names

Generic?

No

Class

• Selective norepinephrine reuptake inhibitor (NRI); antidepressant

Commonly Prescribed for

(bold for FDA approved)

• Major depressive disorder

• Dysthymia

• Panic disorder

• Attention deficit hyperactivity disorder (ADHD)

How the Drug Works

• Boosts neurotransmitter norepinephrine/noradrenaline and may also increase dopamine in prefrontal cortex

• Blocks norepinephrine reuptake pump (norepinephrine transporter)

• Presumably, this increases noradrenergic neurotransmission

• Since dopamine is inactivated by norepinephrine reuptake in frontal cortex which largely lacks dopamine transporters, reboxetine can increase dopamine neurotransmission in this part of the brain

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]